Patient-Reported Outcomes (Pros) From The Phase Iii Imbrave150 Trial Of Atezolizumab (Atezo) Plus Bevacizumab (Bev) Vs Sorafenib (Sor) As First-Line Treatment (Tx) For Patients (Pts) With Unresectable Hepatocellular Carcinoma (Hcc)

Peter R. Galle,Richard S. Finn, Shukui Qin,Masafumi Ikeda,Andrew X. Zhu,Tae-You Kim,Masatoshi Kudo,Valeriy Vladimirovich Breder, Philippe Merle,Ahmed Omar Kaseb,Daneng Li,Sohail Mulla,Wendy Verret,Derek-Zhen Xu,Sairy Hernandez,Juan Liu,Chen Huang,Ho Yeong Lim,Ann-Lii Cheng,Michel Ducreux

JOURNAL OF CLINICAL ONCOLOGY（2020）

引用 39|浏览135

暂无评分

摘要

476Background: Atezo + bev in pts with unresectable HCC who had not received prior systemic therapy has shown statistically significant and clinically meaningful improvement in OS and PFS per indep...

查看译文

关键词

unresectable hepatocellular carcinoma,bevacizumab,phase iii imbrave150 trial,atezolizumab,sorafenib,patient-reported,first-line

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要